{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:01:37Z","timestamp":1790784097013,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.kint.2026.08.030","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:06:19Z","timestamp":1790780779000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression"],"prefix":"10.1016","author":[{"given":"Lesley A.","family":"Inker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hocine","family":"Tighiouart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Hannedouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazeen H.","family":"Jafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart D.","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco P.","family":"Schena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.08.030_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib2","unstructured":"Rashid, I., Heerspink H.J.L., & Inker, L.A. Clinical relevance of a \u226530% Decline in Urine Albumin-to-Creatinine Ratio: A Biomarker-Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD. (Under review)."},{"key":"10.1016\/j.kint.2026.08.030_bib3","unstructured":"Rashid, I., Heerspink H.J.L., & A, Inker, L.A. An albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD. (Under review)."},{"key":"10.1016\/j.kint.2026.08.030_bib4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.kint.2026.08.030_bib5","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.08.030_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","article-title":"Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial","volume":"5","author":"Kamper","year":"1992","journal-title":"American journal of hypertension"},{"key":"10.1016\/j.kint.2026.08.030_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0272-6386(96)90158-4","article-title":"Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial","volume":"27","author":"Ihle","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.030_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","article-title":"Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure","volume":"309","author":"Hannedouche","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2026.08.030_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.08.030_bib13","first-page":"S58","article-title":"Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?","volume":"63","author":"van Essen","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2026.08.030_bib14","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.08.030_bib15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib16","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.08.030_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"326","author":"Lewis","year":"1992","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib19","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.030_bib22","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib23","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib24","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib25","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"New England Journal Medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ki.1992.309","article-title":"Long-term comparison between captopril and nifedipine in the progression of renal insufficiency","volume":"42","author":"Zucchelli","year":"1992","journal-title":"Kidney international"},{"issue":"Suppl 2","key":"10.1016\/j.kint.2026.08.030_bib27","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes care"},{"key":"10.1016\/j.kint.2026.08.030_bib28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib30","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5301\/jn.5000110","article-title":"IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine","volume":"26","author":"Pozzi","year":"2013","journal-title":"Journal of nephrology"},{"key":"10.1016\/j.kint.2026.08.030_bib32","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1681\/ASN.V1081772","article-title":"The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group","volume":"10","author":"Donadio","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.V124791","article-title":"A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy","volume":"12","author":"Donadio","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib34","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib35","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney international"},{"key":"10.1016\/j.kint.2026.08.030_bib36","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","author":"Manno","year":"2009","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 24"},{"key":"10.1016\/j.kint.2026.08.030_bib37","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2004080686","article-title":"Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis","volume":"16","author":"Chan","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199208273270904","article-title":"Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group","volume":"327","author":"Ponticelli","year":"1992","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.030_bib42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney international"},{"key":"10.1016\/j.kint.2026.08.030_bib43","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib44","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.030_bib45","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib46","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1681\/ASN.2012121222","article-title":"Nurse practitioner care improves renal outcome in patients with CKD","volume":"25","author":"Peeters","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib47","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2215\/CJN.07160810","article-title":"A nurse-coordinated model of care versus usual care for stage 3\/4 chronic kidney disease in the community: a randomized controlled trial","volume":"6","author":"Barrett","year":"2011","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"10.1016\/j.kint.2026.08.030_bib48","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.08.030_bib49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"The lancet. Diabetes & endocrinology"},{"key":"10.1016\/j.kint.2026.08.030_bib50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib51","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2026.08.030_bib52","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib53","article-title":"Impact of Using the Race-Free 2021 CKD-EPI Creatinine Equation on Treatment Effects on GFR-Based Endpoints in Clinical Trials","author":"Chaudhari","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.030_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"key":"10.1016\/j.kint.2026.08.030_bib55","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","article-title":"Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.030_bib56","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1002\/sim.9886","article-title":"Handling missing within-study correlations in the evaluation of surrogate endpoints","volume":"42","author":"Collier","year":"2023","journal-title":"Statistics in medicine"},{"key":"10.1016\/j.kint.2026.08.030_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.1689","article-title":"Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial","volume":"8","author":"Beernink","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.kint.2026.08.030_bib58","first-page":"320","article-title":"Glucocorticoids and control of glomerular filtration rate","volume":"10","author":"Baylis","year":"1990","journal-title":"Seminars in nephrology"},{"key":"10.1016\/j.kint.2026.08.030_bib59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ajh\/hpae071","article-title":"Association Between Plasma Aldosterone Concentration and Intraglomerular Hemodynamics in Primary Aldosteronism","volume":"37","author":"Uedono","year":"2024","journal-title":"American journal of hypertension"},{"key":"10.1016\/j.kint.2026.08.030_bib60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.kint.2018.08.024","article-title":"Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx","volume":"95","author":"Butler","year":"2019","journal-title":"Kidney international"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:06:27Z","timestamp":1790780787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826008240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"alternative-id":["S0085253826008240"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.08.030","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}